Zhen Wu

8323651, Dec 4, 2012

May 8, 2009

12/437715

Jijie Gu - Shewsbury MA, US
Chung-Ming Hsieh - Newton MA, US
Zhen Wu - Framingham MA, US
Enrico L. DiGiammarino - Lindenhurst IL, US
Feng Luo - Arlington Heights IL, US
Gerard B. Fox - Barrington Hills IL, US
John E. Harlan - Lake Zurich IL, US
Martin Schmidt - Bensheim, DE
Ralf Loebbert - Speyer, DE
Reinhold Mueller - Schifferstadt, DE
Ulrich Ebert - Mannheim, DE
Volker Nimmrich - Heidelberg, DE

Abbott Laboratories - Abbott Park IL
Abbott GmbH & Co. KG - Wiesbaden-Delkenheim

A61K 39/395
C07H 21/04
C07K 16/00
A61P 25/28
C12N 15/63
C12N 5/10
C12P 21/02

4241431, 435 696, 4353201, 435325, 536 235, 53638822

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid β and advanced glycation-end-products.

20170002075, Jan 5, 2017

Jul 18, 2016

15/213130

- WIESBADEN, DE
- NORTH CHICAGO IL, US
Zhen WU - Framingham MA, US
Enrico L. DiGIAMMARINO - Lindenhurst IL, US
Feng LUO - Arlington Heights IL, US
Gerard B. FOX - Barrington Hills IL, US
John E. HARLAN - Lake Zurich IL, US
Martin SCHMIDT - Bensheim, DE
Ralf LOEBBERT - Speyer, DE
Reinhold MUELLER - Schifferstadt, DE
Ulrich EBERT - Mannheim, DE
Volker NIMMRICH - Heidelberg, DE

C07K 16/28
C07K 16/46
C12P 21/00

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products.